Skip to main content
. 2022 Jan 22;14(2):260. doi: 10.3390/pharmaceutics14020260

Table 3.

Oligonucleotides other than ASOs and siRNAs in clinical development.

Drug Name Target Gene Mode of Action
(Type of Compound)
Therapy Area Latest Stage of Development Company
Lademirsen MIR21 Expression inhibition (miRNA inhibitor) Genitourinary system Phase II Sanofi
MTL-CEBPA CEBPA Expression activation (saRNA) Oncology Phase II Mina Therapeutics
remlarsen MIR29B1 Expression activation (miRNA mimic) Dermatology Phase II Miragen Therapeutics